Phase I Open Label Multicenter Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors.

Trial Profile

Phase I Open Label Multicenter Dose Escalation Study of the Safety and Pharmacokinetics of ME-143 as a Single Agent in Patients With Refractory Solid Tumors.

Completed
Phase of Trial: Phase I

Latest Information Update: 24 Nov 2013

At a glance

  • Drugs ME 143 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Most Recent Events

    • 04 Jun 2012 Status changed from active, no longer recruiting to completed.
    • 03 Apr 2012 Results will be reported at the 2012 American Society of Clinical Oncology (ASCO) Annual Meeting, according to a Marshall Edwards media release.
    • 03 Apr 2012 Status changed from recruiting to active, no longer recruiting, according to a Marshall Edwards media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top